There’s no denying the popularity of weight-loss drugs in the United States, with one in eight adults relying on GLP-1s to ...

Patients know about nausea and vomiting. Now, lawsuits are raising concerns about vision loss.

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

A lifelong commitment to stay thin?

Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...

Thousands of patients are suing over alleged GLP-1 drug injuries. Drugs include Ozempic, Wegovy and Mounjaro.

GLP-1 therapies helped drive a 79% year-over-year increase in strategic pharmaceutical M&A deal value through mid-November ...

Eli Lilly (NYSE:LLY) plans to invest over US$3.5b in a new Pennsylvania manufacturing facility focused on next generation ...

Participating Medicare Part D plans can officially begin covering weight-loss treatment in 2027. The initiative falls under CMS’ voluntary “Better Approaches to Lifestyle and Nutrition for ...

Serena Williams showed off her slimmed-down figure in a chic work outfit, revealing her GLP-1 journey and commitment to ...

Indiana Poison Center reports GLP-1 calls doubled last year; National Poison Data System, America's Poison Centers reports a ...

GLP-1 drugs might lead people to shun alcohol entirely: or the effect may be more nuanced. People might have one drink to ...